DOCSLIB.ORG

Introduction to FDA Review and Approval of Biological Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction to FDA Review and Approval of Biological Products Introduction to FDA Review and Approval of Biological Products Jason Conaty Hogan Lovells US LLP October 14, 2020 Agenda • Basic principles; definitions and jurisdiction – What a biologic is and where it fits relative to drugs, devices, etc. • Pathways to market • Requirements for approval • Expedited programs • Marketing exclusivity Sources of Law • Public Health Servises Act (PHSA) (1944) – Biological products (biologics) – Biosimilars (2010) • Food, Drug, and Cosmetics Act (FDCA) (1938) – Food – Drugs – Medical devices – Cosmetics – Tobacco (2010) Centers • Center for Biologics Evaluation and Research (CBER) • Center for Devices and Radiological Health (CDRH) • Center for Drug Evaluation and Research (CDER) • Center for Food Safety and Applied Nutrition • Center for Tobacco Products • Center for Veterinary Medicine Intended Use • Intended use is the objective intent of the person legally responsible for the product’s labeling • Evidence of intended use – Expressions of the person responsible for labeling or circumstances surrounding the product’s distribution – Look to, e.g., labeling claims, advertising, statements by company or its representatives Drugs FDCA 201(g) • The term “drug” means – articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary; and – articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and – articles (other than food) intended to affect the structure or any function of the body of man or other animals; and – articles intended for use as a component of any [such] article Biologic PHSA 351(i) • The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, . applicable to the prevention, treatment, or cure of a disease or condition of human beings Drug vs Biologic • Similar to a drug, is “applicable to the prevention, treatment, or cure of a disease or condition of human beings” • A subset of articles – Often thought to mean a product derived from a living source (animal or plant), as opposed to chemically synthesized, but not quite so – Some products that fall within the definition of “biological product” have been approved as drugs, but they were “deemed to have been licensed” as biologics in March 2020 Device FDCA 201(h) • Medical devices, like drugs, are articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect structure/function of the body • Subset of articles – Distinguished from a drug in that it does not achieve its primary intended purpose through chemical action within or on the body, or by being metabolized Cosmetic FDCA 201(i) • Article intended to be applied to, or introduced into, the body to cleanse (but not a soap), beautify, promote attractiveness or alter appearance – Claims of effect on structure/function can be problematic, which is why you see claims to “reduce the appearance of wrinkles and fine lines” – FDA has taken the position that the presence of certain ingredients that are active ingredients in drugs make a product a drug, regardless of claims Dietary Supplement FDCA 201(ff) • A product intended to supplement the diet that contains certain types of ingredients (e.g., vitamin, mineral, herb) and is intended for ingestion • Permitted to include structure/function claims subject to disclaimer Tobacco FDCA 201(rr) • A product made or derived from tobacco and intended for human consumption, or any component, part or accessory, but not any such product that meets the statutory definition of drug, device or combination product – Distinction is based on intended use; product intended for use in diagnosis, cure, mitigation, treatment or prevention of disease, or to affect structure/function is not a tobacco product supplement drug device biologic cosmetic tobacco Pathways • Biologics License Application (BLA) – 351(a) BLA – branded innovator pathway – 351(k) biosimilar • New Drug Application (NDA) – 505(b)(1) NDA – branded innovator pathway – 505(j) abbreviated NDA (ANDA) – generic drugs – 505(b)(2) NDA hybrid pathway • Medical devices – Pre-Market Approval (PMA) – 510(k) clearance Combination Products • Therapeutic and diagnostic products that combine drugs, devices, and/or biological products 21 CFR 3.2(e) – Physically, chemically, or otherwise combined or mixed and produced as a single entity; – Packaged together in a single package or as a unit – Packaged separately, but specifically labeled for use with one another • The constituent components (e.g., drug, biologic, device) can be approved under separate marketing applications (NDA, BLA, PMA/510(k)), or under a single marketing application Jurisdiction • Primary mode of action (PMOA) – An investigational product will be assigned to CDER/CBER or CDRH for lead review depending on the PMOA of the product – If the PMOA is “chemical action” then the combination will typically be reviewed as a drug (or biologic as the case may be) • One marketing application, or two? – When a drug or biologic is combined with a device, there is a strong policy preference for the combination drug/device or biologic/device to be approved under a single marketing authorization, typically an NDA or a BLA • Request for Designation (RFD) – The sponsor of an investigational product can submit a RFD to the Office of Combination Products • Intercenter Agreements – Historically, jurisdictional questions had been the subject of three “Intercenter Agreements” that were entered into by CDER, CBER and CDRH in 1991 – Much of what the agreements covered has since been formalized by rulemaking and guidance Biological Products Protein Therapeutics, BLAs, Biosimilars Biologics Price Competition and Innovation Act (BPCIA) • Enacted on March 23, 2010, as part of the ACA • Created a pathway for the approval of biosimilars in the U.S. • Created a pathway for making interchangeability determinations for biosimilars • Established 12-year reference biologic exclusivity • Established a system for pre-approval patent litigation between pioneers and biosimilars • The BPCIA also amended the definition of biological product to include added the terms “protein (except any chemically synthesized polypeptide)” • Established a 10 year transition mechanism for consolidating the approval of all biological products under the biologics system (= Protein products) • In December 2019, Congress made a further amendment, striking the exception for “chemically synthesized polypeptides” • As of March 23, 2020, NDAs for protein products were “deemed to be a licensed” under BLAs Proteins • The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product . Proteins Previously Regulated as • insulin products Drugs • somatropin products • chorionic gonadotropin products • desirudin products • follitropin products, urofollitropin products, and menotropins products • hyaluronidase products • imiglucerase products • mecasermin products • pancrelipase products • pegademase products • pegvisomant products • sacrosidase products • somatropin products • taliglucerase alfa products and velaglucerase alfa products • thyrotropin alfa products Regulatory Definition of Protein • “A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.” • “When two or more amino acid chains in an amino acid polymer are associated with each other in a manner that occurs in nature, the size of the amino acid polymer . will be based on the total number of amino acids in those chains, and will not be limited to the number of amino acids in a contiguous sequence.” 21 CFR 600.3(h)(6 “Full” 351(a) BLA • Under 351(a), a BLA will be approved if it: – Demonstrates the product is safe, pure, and potent – Demonstrates the manufacturing facility meets standards designed to assure that the product continues to be safe, pure, and potent • The regulations add only that the applicant “Shall submit data from nonclinical and clinical studies which demonstrate that the manufactured product meets prescribed requirements of safety, purity and potency.” 21 CFR 601.2 Historical Fexibility • Diversity of products, from blood to vaccines to allergens • Biologics Act (1902): regulated manufacturing and labeling but not the products themselves • Recodified as PHSA (1944): “safety, purity, and potency” • FDCA (1938) and its major amendments left the regulation of biologics untouched • Administration shunted about before landing at FDA in 1972, while philosophy and standards of biologics regulation remained nebulous • FDAMA (1997), Congress instructed FDA to “minimize differences in the review and approval” of biologics and drugs Standard for Approval of a “Full” BLA • The substantive content of a BLA for a modern therapeutic protein is generally seen as coincident with that of a full NDA under 505(b)(1) • In practice, a BLA is expected to conform to the ICH standards for preparing the Common Technical Document (ICH-CTD) • The CTD includes placeholders for specific kinds of preclinical and clinical data • Must contain sufficient data to show that the product is safe, pure, and potent • Each product is approved with a labeling and claims, and each claim must be supported by “substantial evidence” “Substantial Evidence” of Effectiveness • “Substantial
Load more

Recommended publications
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Elelyso™ (Taliglucerase Alfa)
    Elelyso™ (taliglucerase alfa) (Intravenous) Document Number: IC-0105 Last Review Date: 07/01/2020 Date of Origin: 03/07/2013 Dates Reviewed: 12/2013, 02/2014, 09/2014, 07/2015, 07/2016, 08/2016, 08/2017, 07/2018, 07/2019, 07/2020 I. Length of Authorization Coverage will be for 12 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC unit]: • Elelyso 200 unit powder for injection: 35 vials every 14 days B. Max Units (per dose and over time) [HCPCS Unit]: • 700 billable units every 14 days 1,9,10,11,12,13 III. Initial Approval Criteria Coverage is provided in the following conditions: • Patient at least 4 years of age; AND Universal Criteria • Must be used as a single agent; AND Type 1 Gaucher’s Disease † Ф • Patient has a documented diagnosis of Type 1 Gaucher Disease as confirmed by a beta- glucosidase leukocyte (BGL) test with significantly reduced or absent glucocerebrosidase enzyme activity; AND • Adults only (i.e., patients at least 18 years or older): Patient’s disease results in one or more of the following: − Anemia [i.e., hemoglobin less than or equal to 11 g/dL (women) or 12 g/dL (men) ] not attributed to iron, folic acid or vitamin B12 deficiency; OR − Moderate to severe hepatomegaly (liver size 1.25 or more times normal) or splenomegaly (spleen size 5 or more times normal); OR Proprietary & Confidential © 2020 Magellan Health, Inc. − Skeletal disease (e.g. lesions, remodeling defects and/or deformity of long bones, osteopenia/osteoporosis, etc.); OR − Symptomatic disease(e.g.
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
    Review Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines Puna Maya Maharjan 1 and Sunghwa Choe 2,3,* 1 G+FLAS Life Sciences, 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Korea; punamaya.maharjan@gflas.com 2 G+FLAS Life Sciences, 38 Nakseongdae-ro, Gwanak-gu, Seoul 08790, Korea 3 School of Biological Sciences, College of Natural Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea * Correspondence: [email protected] Abstract: The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco- produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical Citation: Maharjan, P.M.; Choe, S. trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more Plant-Based COVID-19 Vaccines: neutralizing antibody responses compared to those present in a convalescent patient’s plasma.
    [Show full text]
  • FDA's Interpretation of the “Deemed to Be a License”
    FDA WATCH FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovations Act A look at how the FDA will administer the transition of NDAs to BLAs n 2010, Congress passed, and President “deemed to be a license” provision and a Product Time to Approval (months) Aprotinin --- 4 Obama signed, the Patient Protection draft Q&A guidance document providing Beractant --- 1 Iand Affordable Care Act, within which additional details regarding the imple- Calfactant 35 is the Biologics Price Competition and In- mentation of the provision. Choriogonadotropin alfa 10 novations Act (BPCIA)2 that codified the This article provides a summary of how Chorionic gonadotropin* --- ability of the Food and Drug Administra- the FDA will administer the transition of Chymopapain --- Desirudin 33 tion (FDA) to review and approve biosimi- NDAs to BLAs, as described in these two Follitropin alfa 22 lar medicinal products. To harmonize the guidance documents. Follitropin alfa/beta 50 regulatory system for biological products Follicle stimulating hormone --- in the U.S., the BPCIA included Section FDA’s plans for Implementation of the Hyalurionidase 9 7002(e) which requires that all marketing “deemed to be a license” Section of Imiglucerase --- Insulin aspart 21 applications for biological products (as de- the BPCIA Insulin degludec 48 fined in the statute) be submitted as Bio- As written, Section 7002(e)(4) only ap- Insulin detemir 30 logics License Applications (BLA) under plies to approved NDAs and requires their Insulin glargine 12 the Public Health Services Act (PHSA). conversion to BLAs on the date that is 10 Insulin glulisine 10 Furthermore, Section 7002(e)(4) of the years after enactment of the BPCIA.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Poster Session Abstracts
    Poster Session Abstracts Poster sessions will be in the Harbor Ballroom on: Tuesday, March 1 from 4:30‐6:30pm Wednesday, March 2 from 4:30‐6:00pm. No photos or videos are permitted of any oral or poster sessions. The only exception is at the official poster sessions if the author is present and gives permission. Any poster numbers not listed will not be presented as the author is unable to attend the conference. It is the policy of WORLDSymposium to publish all abstracts with the list of authors exactly as the abstract was submitted to WORLDSymposium. The first author of the submitted abstract will be listed as the presenting author on the Preliminary Program, Agenda, and Poster List. Poster # First Author Abstract Title 1 Magy Abdelwahab Long‐term follow up and sudden unexpected death in Gaucher disease type 3 in Egypt 2 Magy Abdelwahab Ocular abnormalities in Egyptian Gaucher disease patients 3 Walter Acosta Lectin‐mediated delivery of α‐L‐iduronidase: a novel approach for MPS I enzyme replacement therapy 4 Elma Aflaki iPSC‐derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism demonstrate the potential of a new glucocerebrosidase chaperone 5 Nicholas Agard Evolving improved therapeutic proteins for treating Fabry disease 6 Patricio Aguiar Prognostic model for hearing loss in Fabry disease 7 Patricio Aguiar Urinary type IV collagen: better than albuminuria to identify incipient Fabry nephropathy 8 Alia Ahmed Association of physical symptom score (PSS) with age and cognitive measures in attenuated mucopolysaccharidosis
    [Show full text]
  • Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012
    J Inherit Metab Dis (2012) 35 (Suppl 1):S1–S182 DOI 10.1007/s10545-012-9512-z ABSTRACTS Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012 This supplement was not sponsored by outside commercial interests. It was funded entirely by the SSIEM. 01. Amino Acids and PKU O-002 NATURAL INHIBITORS OF CARNOSINASE (CN1) O-001 Peters V1 ,AdelmannK2 ,YardB2 , Klingbeil K1 ,SchmittCP1 , Zschocke J3 3-HYDROXYISOBUTYRIC ACID DEHYDROGENASE DEFICIENCY: 1Zentrum für Kinder- und Jugendmedizin de, Heidelberg, Germany IDENTIFICATION OF A NEW INBORN ERROR OF VALINE 2Universitätsklinik, Mannheim, Germany METABOLISM 3Humangenetik, Innsbruck, Austria Wanders RJA1 , Ruiter JPN1 , Loupatty F.1 , Ferdinandusse S.1 , Waterham HR1 , Pasquini E.1 Background: Carnosinase degrades histidine-containing dipeptides 1Div Metab Dis, Univ Child Hosp, Amsterdam, Netherlands such as carnosine and anserine which are known to have several protective functions, especially as antioxidant agents. We recently Background, Objectives: Until now only few patients with an established showed that low carnosinase activities protect from diabetic nephrop- defect in the valine degradation pathway have been identified. Known athy, probably due to higher histidine-dipeptide concentrations. We deficiencies include 3-hydroxyisobutyryl-CoA hydrolase deficiency and now characterized the carnosinase metabolism in children and identi- methylmalonic semialdehyde dehydrogenase (MMSADH) deficiency. On fied natural inhibitors of carnosinase. the other hand many patients with 3-hydroxyisobutyric aciduria have been Results: Whereas serum carnosinase activity and protein concentrations described with a presumed defect in the valine degradation pathway. To correlate in adults, children have lower carnosinase activity although pro- identify the enzymatic and molecular defect in a group of patients with 3- tein concentrations were within the same level as for adults.
    [Show full text]
  • Culturas Celulares De Tabaco BY2 Para a Produção De Biofármacos: O Papel Da Metilação Do ADN Na Expressão Do Transgene
    Leonor Brás de Oliveira Bandeira de Melo Licenciada em Biologia Culturas Celulares de Tabaco BY2 para a Produção de Biofármacos: O Papel da Metilação do ADN na Expressão do Transgene Dissertação para obtenção do Grau de Mestre em Bioquímica para a Saúde Orientador: Doutora Rita Abranches, ITQB NOVA Dezembro 2017 Leonor Brás de Oliveira Bandeira de Melo Licenciada em Biologia Culturas Celulares de Tabaco BY2 para a Produção de Biofármacos: O Papel da Metilação do ADN na Expressão do Transgene Dissertação para obtenção do Grau de Mestre em Bioquímica para a Saúde Orientador: Doutora Rita Abranches, ITQB NOVA Presidente: Doutor Pedro Manuel H. M. Matias Arguente: Doutora Helena Manuela Gil Azinheira Vogais: Doutora Margarida Archer Franco Frazão Doutora Rita Sobral Moutinho Abranches Instituto de Tecnologia Química e Biológica Dezembro 2017 Culturas Celulares de Tabaco BY2 para a Produção de Biofármacos: O Papel da Metilação do ADN na Expressão do Transgene Copyright © Leonor Brás de Oliveira Bandeira de Melo, ITQB NOVA, UNL O Instituto de Tecnologia Química e Biológica António Xavier e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objetivos educacionais ou de investigação, não comerciais, desde que seja dado credito ao autor e
    [Show full text]